{"id":1333,"date":"2023-07-06T14:05:34","date_gmt":"2023-07-06T14:05:34","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=1333"},"modified":"2023-07-06T14:08:12","modified_gmt":"2023-07-06T14:08:12","slug":"evox-therapeutics-acquires-exosome-aav-technology","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/","title":{"rendered":"Evox Therapeutics Acquires Exosome AAV Technology"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_0d5dcf51d8ac455481ffd5d3d18a47f4\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg 1920w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header-300x169.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header-1024x576.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header-768x432.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header-1000x563.jpg 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header-475x267.jpg 475w\" type=\"image\/jpeg\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Evox Therapeutics Acquires Exosome AAV Technology<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<section class=\"text-block  padding-large\" id=\"block_da09b6f1cae4fd9367412412cbf8d51c\">\n    <div class=\"ed-container\">\n        <div class=\"text-block__content\">\n                        \n\n<p>ARC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform. The agreement includes all intellectual property rights, as well as securing exclusive access to certain engineering and manufacturing rights associated with it.&nbsp;<\/p>\n\n\n\n<p>This technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective way to improve AAV delivery, and to shield AAVs from neutralising antibodies.<\/p>\n\n\n\n<p>Focused on developing an entirely new class of therapeutics for the treatment of severe rare diseases, Evox uses its proprietary&nbsp;DeliverEX\u00ae&nbsp;technology to engineer exosomes to facilitate drug delivery to organs of interest, including the brain and the central nervous system. This approach has potential to address some of the limitations of genetic medicines such as gene therapy, gene editing and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies.<\/p>\n\n\n\n<p>It is backed by leading life sciences venture capital groups including Redmile and OrbiMed, and is supported by a comprehensive intellectual property portfolio.<\/p>\n\n\n\n<p>\u201cWe are pleased to now own this technology and look forward to applying it in future exosome AAV programs. This acquisition further adds to our dominant intellectual property portfolio of patents that cover key aspects needed to develop and commercialise exosome therapeutics including their design, composition, and manufacture,\u201d said&nbsp;Per Lundin, PhD, Chief Business Officer &amp; Co-Founder of Evox Therapeutics. \u201cThis is part of our long-term business strategy of leveraging improved exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors.\u201d<\/p>\n\n\n        <\/div>\n    <\/div>\n<\/section>\n\n\n    <section class=\"news-archive \" id=\"block_31fc9f52098d2a072646f214d40804e7\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" target=\"_self\">\n\t\t\t\tAccession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg 1110w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-300x201.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1024x685.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-768x513.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1000x668.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tChildbase Partnership announces new Garsington Road day nursery opening at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg 2402w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\" target=\"_self\">\n\t\t\t\tOxa Raises $103m in Series D First Close to supercharge Industrial Mobility Automation\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>RC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform.<\/p>\n","protected":false},"author":3,"featured_media":1335,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[4276],"class_list":["post-1333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-science-and-innovation"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evox Therapeutics Acquires Exosome AAV Technology - ARC Oxford<\/title>\n<meta name=\"description\" content=\"RC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evox Therapeutics Acquires Exosome AAV Technology - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"RC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-06T14:05:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-06T14:08:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"liamjoyce\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"liamjoyce\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/\"},\"author\":{\"name\":\"liamjoyce\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04\"},\"headline\":\"Evox Therapeutics Acquires Exosome AAV Technology\",\"datePublished\":\"2023-07-06T14:05:34+00:00\",\"dateModified\":\"2023-07-06T14:08:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/\"},\"wordCount\":299,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg\",\"keywords\":[\"Science and innovation\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/\",\"name\":\"Evox Therapeutics Acquires Exosome AAV Technology - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg\",\"datePublished\":\"2023-07-06T14:05:34+00:00\",\"dateModified\":\"2023-07-06T14:08:12+00:00\",\"description\":\"RC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evox Therapeutics Acquires Exosome AAV Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04\",\"name\":\"liamjoyce\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g\",\"caption\":\"liamjoyce\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/liamjoyce\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evox Therapeutics Acquires Exosome AAV Technology - ARC Oxford","description":"RC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/","og_locale":"en_US","og_type":"article","og_title":"Evox Therapeutics Acquires Exosome AAV Technology - ARC Oxford","og_description":"RC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform.","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/","og_site_name":"ARC Oxford","article_published_time":"2023-07-06T14:05:34+00:00","article_modified_time":"2023-07-06T14:08:12+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg","type":"image\/jpeg"}],"author":"liamjoyce","twitter_card":"summary_large_image","twitter_misc":{"Written by":"liamjoyce","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/"},"author":{"name":"liamjoyce","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04"},"headline":"Evox Therapeutics Acquires Exosome AAV Technology","datePublished":"2023-07-06T14:05:34+00:00","dateModified":"2023-07-06T14:08:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/"},"wordCount":299,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg","keywords":["Science and innovation"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/","name":"Evox Therapeutics Acquires Exosome AAV Technology - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg","datePublished":"2023-07-06T14:05:34+00:00","dateModified":"2023-07-06T14:08:12+00:00","description":"RC Oxford based biotech Evox therapeutics, a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, has purchased Codiak Biosciences\u2019 engEx-AAV\u2122 technology platform.","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2023\/07\/Exosome-header.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2023\/07\/06\/evox-therapeutics-acquires-exosome-aav-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Evox Therapeutics Acquires Exosome AAV Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04","name":"liamjoyce","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g","caption":"liamjoyce"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/liamjoyce\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=1333"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1333\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/1335"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=1333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=1333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=1333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}